For a vaccine to work at its best, it needs to be delivered where it’s most accessible to dendritic cells. However, there are many different kinds of dendritic cells, and they’re not distributed uniformly throughout the body.
In a paper published in Science Immunology, the team, led by senior co-authors JAX Assistant Professor Adam Williams, Ph.D. and Stephanie Eisenbarth, M.D. Ph.D., of Yale, showed that dendritic cells known as cDC2s (for CD11b+ migratory type 2 conventional DCs) are both necessary and sufficient for robust Tfh cell induction.
Working with mice that lack a protein needed for cDC2 mobility, the team demonstrated that Tfh cells were not induced and antibodies not produced following vaccination, even in the presence of other, functional dendritic cells.